Assessing the role of ADAM10 in Trastuzumab treatment and resistance

<p>Overexpression of the HER2 receptor occurs in about 15-20% of all breast cancers and is correlated with poor prognosis. Trastuzumab (Herceptin®), a monoclonal antibody targeting HER2, was shown to prolong survival of these patients. However, primary or acquired resistance remains a drawback...

詳細記述

書誌詳細
第一著者: Feldinger, K
その他の著者: Kong, A
フォーマット: 学位論文
言語:English
出版事項: 2012
主題:

類似資料